Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity

International Immunopharmacology

Volumn 14, Issue 4, 2012, Pages 550-557

  Smith, Lynnae M ^a   Klaver, Andrea C ^a   Coffey, Mary P ^a   Dang, Loan ^b   Loeffler, David A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

Alpha synuclein; Antibodies; Intravenous immunoglobulin; Oligomers; Thioflavin T; Western blots

Indexed keywords

ALPHA SYNUCLEIN; IMMUNOGLOBULIN G; OLIGOMER; PHOSPHATE BUFFERED SALINE; THIOFLAVINE;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GEL; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NEUROBLASTOMA CELL; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICROSCOPY, ELECTRON, TRANSMISSION; NEUROBLASTOMA; NEURONS; PROTEIN BINDING; PROTEIN CONFORMATION; THIAZOLES;

EID: 84867593766     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2012.09.007     Document Type: Article

References (63)

1. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, and A. Dutra Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
2. T. Gasser Genetics of Parkinson's disease Curr Opin Neurol 18 2005 363 369
3. J.L. Eriksen, S. Przedborski, and L. Petrucelli Gene dosage and pathogenesis of Parkinson's disease Trends Mol Med 11 2005 91 96
4. S. Winkler, J. Hagenah, S. Lincoln, M. Heckman, K. Haugarvoll, and K. Lohmann-Hedrich alpha-Synuclein and Parkinson disease susceptibility Neurology 69 2007 1745 1750
5. M.C. Chartier-Harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay, and S. Lincoln Alpha-synuclein locus duplication as a cause of familial Parkinson's disease Lancet 364 2004 1167 1169
6. O. Chiba-Falek, G.J. Lopez, and R.L. Nussbaum Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients Mov Disord 21 2006 1703 1708
7. J. Gründemann, F. Schlaudraff, and B. Liss UV-laser microdissection and mRNA expression analysis of individual neurons from postmortem Parkinson's disease brains Methods Mol Biol 755 2011 363 374
8. K.A. Conway, S.J. Lee, J.C. Rochet, T.T. Ding, R.E. Williamson, and P.T. Lansbury Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy Proc Natl Acad Sci U S A 97 2000 571 576
9. C. Haass, and D.J. Selkoe Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide Nat Rev Mol Cell Biol 8 2007 101 112
10. B. Winner, R. Jappelli, S.K. Maji, P.A. Desplats, L. Boyer, and S. Aigner In vivo demonstration that alpha-synuclein oligomers are toxic Proc Natl Acad Sci U S A 108 2011 4194 4199
11. G.M. Halliday, and H. McCann Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms Exp Neurol 209 2008 12 21
12. A. Sidhu, C. Wersinger, C.E. Moussa, and P. Vernier The role of alpha-synuclein in both neuroprotection and neurodegeneration Ann N Y Acad Sci 1035 2004 250 270
13. O.M. El-Agnaf, K.E. Paleologou, B. Greer, A.M. Abogrein, J.E. King, and S.A. Salem A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders FASEB J 18 2004 1315 1317
14. D.A. Amer, G.B. Irvine, and O.M. El-Agnaf Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders Exp Brain Res 173 2006 223 233
15. K. Beyer, and A. Ariza The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies Curr Med Chem 15 2008 2748 2759
16. M. Caruana, T. Högen, J. Levin, A. Hillmer, A. Giese, and N. Vassallo Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds FEBS Lett 585 2011 1113 1120
17. W. Zhang, T. Wang, Z. Pei, D.S. Miller, X. Wu, and M.L. Block Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease FASEB J 19 2005 533 542
18. Y. Couch, L. Alvarez-Erviti, N.R. Sibson, M.J. Wood, and D.C. Anthony The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation J Neuroinflammation 8 2001 166
19. A. Klegeris, and P.L. McGeer Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112 Biochem Biophys Res Commun 357 2007 1096 1099
20. O.M. El-Agnaf, S.A. Salem, K.E. Paleologou, L.J. Cooper, N.J. Fullwood, and M.J. Gibson Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma FASEB J 17 2003 1945 1947
21. S.J. Lee Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease J Mol Neurosci 34 2008 17 22
22. O.M. El-Agnaf, S.A. Salem, K.E. Paleologou, M.D. Curran, M.J. Gibson, and J.A. Court Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease FASEB J 20 2006 419 425
23. T. Tokuda, M.M. Qureshi, M.T. Ardah, S. Varghese, S.A. Shehab, and T. Kasai Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease Neurology 75 2010 1766 1772
24. K.A. Bruggink, H.B. Kuiperij, M.M. Verbeek, O.M. El-Agnaf, and T. Tokuda Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease Neurology 77 2010 510 511
25. B. Mollenhauer, J.J. Locascio, W. Schulz-Schaeffer, F. Sixel-Döring, C. Trenkwalder, and M.G. Schlossmacher α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study Lancet Neurol 10 2011 230 240
26. M.B. Aerts, R.A. Esselink, W.F. Abdo, B.R. Bloem, and M.M. Verbeek CSF α-synuclein does not differentiate between parkinsonian disorders Neurobiol Aging 33 2012 430 [e1-3. Epub 2011 Jan 13]
27. L. Parnetti, D. Chiasserini, G. Bellomo, D. Giannandrea, C. De Carlo, and M.M. Qureshi Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias Mov Disord 26 2011 1428 1435
28. J.Y. Li, E. Englund, J.L. Holton, D. Soulet, P. Hagell, and A.J. Lees Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation Nat Med 14 2008 501 503
29. P. Desplats, H.J. Lee, E.J. Bae, C. Patrick, E. Rockenstein, and L. Crews Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein Proc Natl Acad Sci U S A 106 2009 13010 13015
30. J.H. Kordower, H.B. Dodiya, A.M. Kordower, B. Terpstra, K. Paumier, and L. Madhavan Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat Neurobiol Dis 43 2011 552 557
31. C. Krammer, H.M. Schätzl, and I. Vorberg Prion-like propagation of cytosolic protein aggregates: insights from cell culture models Prion 3 2009 206 212
32. E. Masliah, E. Rockenstein, A. Adame, M. Alford, L. Crews, and M. Hashimoto Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease Neuron 46 2005 857 868
33. E. Masliah, E. Rockenstein, M. Mante, L. Crews, B. Spencer, and A. Adame Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease PLoS One 6 2011 e19338
34. L.M. Patrias, A.C. Klaver, M.P. Coffey, and D.A. Loeffler Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations Clin Exp Immunol 161 2010 527 535
35. N.S. Scheinfeld, and J.E. Godwin Intravenous immunoglobulin. Emedicine: medscape reference: drugs, diseases, and procedures updated 2 August 2011 http://emedicine.medscape.com/article/210367-overview Accessed 24 August 2011
36. F. Nimmerjahn, and J.V. Ravetch Anti-inflammatory actions of intravenous immunoglobulin Annu Rev Immunol 26 2008 513 533
37. R.C. Dodel, Y. Du, C. Depboylu, H. Hampel, L. Frölich, and A. Haag Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease J Neurol Neurosurg Psychiatry 75 2004 1472 1474
38. N.R. Relkin, P. Szabo, B. Adamiak, T. Burgut, C. Monthe, and R.W. Lent 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease Neurobiol Aging 30 2009 1728 1736
39. W.R. Shankle, and J. Hara Longitudinal measure of IVIG treatment effect in patients with Alzheimer's and Lewy body disease Alzheimers Dement 5 2009 430
40. K. Nanri, M. Okita, M. Takeguchi, T. Taguchi, T. Ishiko, and H. Saito Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia Intern Med 48 2009 783 790
41. M. Zouali, and B.D. Stollar Thymine and guanine base specificity of human myeloma proteins with anti-DNA activity J Clin Invest 78 1986 1173 1178
42. J. Kuby Immunology 1992 W.H. Freeman and Company New York 100 101
43. R.V. Diemel, H.G. ter Hart, G.J. Derksen, A.H. Koenderman, and R.C. Aalberse Characterization of immunoglobulin G fragments in liquid intravenous immunoglobulin products Transfusion 45 2005 1601 1609
44. A.C. Klaver, J.M. Finke, J. Digambaranath, M. Balasubramaniam, and D.A. Loeffler Antibody levels to Aβ1-42 conformations differ between intravenous immunoglobulins Int Immunopharmacol 10 2010 115 119
45. A.L. Biere, S.J. Wood, J. Wypych, S. Steavenson, Y. Jiang, and D. Anafi Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs J Biol Chem 275 2000 34574 34579
46. L.C. Serpell, J. Berriman, R. Jakes, M. Goedert, and R.A. Crowther Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation Proc Natl Acad Sci U S A 97 2000 4897 4902
47. V.N. Uversky, J. Li, P. Souillac, I.S. Millett, S. Doniach, and R. Jakes Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins J Biol Chem 277 2002 11970 11978
48. M. Yonetani, T. Nonaka, M. Masuda, Y. Inukai, T. Oikawa, and S. Hisanaga Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant J Biol Chem 284 2009 7940 7950
49. H. LeVine III Thioflavine T, interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution Protein Sci 2 1993 404 410
50. J.D. Harper, and P.T. Lansbury Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins Annu Rev Biochem 66 1997 385 407
51. B.I. Giasson, I.V. Murray, J.Q. Trojanowski, and V.M. Lee A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly J Biol Chem 276 2001 2380 2386
52. T. Näsström, S. Gonçalves, C. Sahlin, E. Nordström, V. Screpanti Sundquist, and L. Lannfelt Antibodies against alpha-synuclein reduce oligomerization in living cells PLoS One 6 2011 e27230
53. B.D. van Rooijen, M.M. Claessens, and V. Subramaniam Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease Curr Protein Pept Sci 11 2010 334 342
54. N.P. Reynolds, A. Soragni, M. Rabe, D. Verdes, E. Liverani, and S. Handschin Mechanism of membrane interaction and disruption by α-synuclein J Am Chem Soc 133 2011 19366 19375
55. Y. Liu, M. Qiang, Y. Wei, and R. He A novel molecular mechanism for nitrated {alpha}-synuclein-induced cell death J Mol Cell Biol 3 2011 239 249
56. T.L. Vassilev, M.D. Kazatchkine, J.P. Duong Van Huyen, M. Mekrache, E. Bonnin, and J.C. Mani Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg) Blood 93 1999 3624 3631
57. J. Arredondo, A.I. Chernyavsky, A. Karaouni, and S.A. Grando Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus Am J Pathol 167 2005 1531 1544
58. V. Leytin, S. Mykhaylov, A.F. Starkey, D.J. Allen, H. Lau, and H. Ni Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia Br J Haematol 133 2006 78 82
59. J. Winkler, S. Kroiss, M.L. Rand, I. Azzouzi, K.W. Annie Bang, and O. Speer Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin Br J Haematol 156 2012 508 515
60. K. Nakatani, S. Takeshita, H. Tsujimoto, and I. Sekine Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-alpha-stimulated endothelial cells via a mitochondria-dependent pathway Clin Exp Immunol 127 2002 445 454
61. S. Takeshita, H. Tsujimoto, and K. Nakatani Intravenous immunoglobulin preparations promote apoptosis in lipopolysaccharide-stimulated neutrophils via an oxygen-dependent pathway in vitro APMIS 113 2005 269 277
62. P. Haussermann, W. Kuhn, H. Przuntek, and T. Muller Integrity of the blood-cerebrospinal fluid barrier in early Parkinson's disease Neurosci Lett 300 2001 182 184
63. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul, and D.M. Holtzman Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease Proc Natl Acad Sci USA 98 2001 8850 8855